Identification of determinants of glucose-dependent insulinotropic polypeptide receptor that interact with N-terminal biologically active region of the natural ligand

Molecular Pharmacology

Volumn 77, Issue 4, 2010, Pages 547-558

  Yaqub, Tahir ^a   Tikhonova, Irina G ^a   Lättig, Jens ^a   Magnan, Remi ^a   Laval, Marie ^a   Escrieut, Chantal ^a   Boulègue, Cyril ^b   Hewage, Chandralal ^c   Fourmy, Daniel ^a  

^a INSERM   (France)

^b MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CYCLIC AMP; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR; GLUTAMINE; PHENYLALANINE; TYROSINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING SITE; CELL STRAIN HEK293; CONFOCAL MICROSCOPY; CRYSTAL STRUCTURE; FLOW CYTOMETRY; GENE MUTATION; HUMAN; HUMAN CELL; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; SITE DIRECTED MUTAGENESIS;

AMINO ACID SEQUENCE; CELLS, CULTURED; CYCLIC AMP; GASTRIC INHIBITORY POLYPEPTIDE; HUMANS; LIGANDS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PROTEIN STRUCTURE, SECONDARY; RECEPTORS, GASTROINTESTINAL HORMONE;

EID: 77950195236     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.060111     Document Type: Article

References (37)

1. Baggio LL and Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131-2157.
2. Ballesteros JA and Weinstein H (1995) Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G-protein coupled receptors. Methods Neurosci 25:366-428.
3. Betancourt MR and Thirumalai D (1999) Pair potentials for protein folding: choice of reference states and sensitivity of predicted native states to variations in the interaction schemes. Protein Sci 8:361-369.
4. Brown JC (1974) Candidate hormones of the gut. 3. Gastric inhibitory polypeptide (GIP). Gastroenterology 67:733-734.
5. Castro M, Nikolaev VO, Palm D, Lohse MJ, and Vilardaga JP (2005) Turn-on switch in parathyroid hormone receptor by a two-step parathyroid hormone binding mechanism. Proc Natl Acad Sci USA 102:16084-16089.
6. Chenna R, Sugawara H, Koike T, Lopez R, Gibson TJ, Higgins DG, and Thompson JD (2003) Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res 31:3497-3500.
7. Di Paolo E, De Neef P, Moguilevsky N, Petry H, Bollen A, Waelbroeck M, and Robberecht P (1998) Contribution of the second transmembrane helix of the secretin receptor to the positioning of secretin. FEBS Lett 424:207-210.
8. Di Paolo E, Vilardaga JP, Petry H, Moguilevsky N, Bollen A, Robberecht P, and Waelbroeck M (1999) Role of charged amino acids conserved in the vasoactive intestinal polypeptide/secretin family of receptors on the secretin receptor functionality. Peptides 20:1187-1193.
9. Dong M, Gao F, Pinon DI, and Miller LJ (2008) Insights into the structural basis of endogenous agonist activation of family B G protein-coupled receptors. Mol Endocrinol 22:1489-1499.
10. Dufresne M, Seva C, and Fourmy D (2006) Cholecystokinin and gastrin receptors. Physiol Rev 86:805-847.
11. Gardella TJ, Luck MD, Fan MH, and Lee C (1996) Transmembrane residues of the parathyroid hormone (PTH)/PTH-related peptide receptor that specifically affect binding and signaling by agonist ligands. J Biol Chem 271:12820-12825.
12. Gault VA, Hunter K, Irwin N, Green BD, Greer B, Harriott P, O'Harte FP, and Flatt PR (2007) Characterisation and biological activity of Glu3 amino acid substituted GIP receptor antagonists. Arch Biochem Biophys 461:263-274.
13. Gault VA, O'Harte FP, Harriott P, and Flatt PR (2002) Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochem Biophys Res Commun 290:1420-1426.
14. Gether U (2000) Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev 21:90-113.
15. Gigoux V, Escrieut C, Fehrentz JA, Poirot S, Maigret B, Moroder L, Gully D, Martinez J, Vaysse N, and Fourmy D (1999) Arginine 336 and asparagine 333 of the human cholecystokinin-A receptor binding site interact with the penultimate aspartic acid and the C-terminal amide of cholecystokinin. J Biol Chem 274:20457-20464.
16. Gremlich S, Porret A, Hani EH, Cherif D, Vionnet N, Froguel P, and Thorens B (1995) Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor. Diabetes 44:1202-1208.
17. Hinke SA, Gelling R, Manhart S, Lynn F, Pederson RA, Kühn-Wache K, Rosche F, Demuth HU, Coy D, and McIntosh CH (2003) Structure-activity relationships of glucose-dependent insulinotropic polypeptide (GIP). Biol Chem 384:403-407.
18. Hinke SA, Manhart S, Pamir N, Demuth H, W Gelling R, Pederson RA, and McIntosh CH (2001) Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP). Biochim Biophys Acta 1547:143-155.
19. Hinke SA, Manhart S, Speck M, Pederson RA, Demuth HU, and McIntosh CH (2004) In depth analysis of the N-terminal bioactive domain of gastric inhibitory polypeptide. Life Sci 75:1857-1870.
20. Horn F, Bettler E, Oliveira L, Campagne F, Cohen FE, and Vriend G (2003) GPCRDB information system for G protein-coupled receptors. Nucleic Acids Res 31:294-297.
21. Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Chien EY, Lane JR, Ijzerman AP, and Stevens RC (2008) The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322:1211-1217.
22. Jörnvall H, Carlquist M, Kwauk S, Otte SC, McIntosh CH, Brown JC, and Mutt V (1981) Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP). FEBS Lett 123:205-210.
23. Kieffer TJ (2003) GIP or not GIP? That is the question. Trends Pharmacol Sci 24:110-112.
24. Malde AK, Srivastava SS, and Coutinho EC (2007) Understanding interactions of gastric inhibitory polypeptide (GIP) with its G-protein coupled receptor through NMR and molecular modeling. J Pept Sci 13:287-300.
25. Mentlein R, Gallwitz B, and Schmidt WE (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829-835.
26. Moody AJ, Thim L, and Valverde I (1984) The isolation and sequencing of human gastric inhibitory peptide (GIP). FEBS Lett 172:142-148.
27. Murphy LR, Wallqvist A, and Levy RM (2000) Simplified amino acid alphabets for protein fold recognition and implications for folding. Protein Eng 13:149-152.
28. Neumann JM, Couvineau A, Murail S, Lacapère JJ, Jamin N, and Laburthe M (2008) Class-B GPCR activation: is ligand helix-capping the key? Trends Biochem Sci 33:314-319.
29. Parthier C, Kleinschmidt M, Neumann P, Rudolph R, Manhart S, Schlenzig D, Fanghänel J, Rahfeld JU, Demuth HU, and Stubbs MT (2007) Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor. Proc Natl Acad Sci USA 104:13942-13947.
30. Perret J, Van Craenenbroeck M, Langer I, Vertongen P, Gregoire F, Robberecht P, and Waelbroeck M (2002) Mutational analysis of the glucagon receptor: similarities with the vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide (PACAP)/secretin receptors for recognition of the ligand's third residue. Biochem J 362:389-394.
31. Runge S, Wulff BS, Madsen K, Bräuner-Osborne H, and Knudsen LB (2003) Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity. Br J Pharmacol 138:787-794.
32. Silvente-Poirot S, Escrieut C, Galès C, Fehrentz JA, Escherich A, Wank SA, Martinez J, Moroder L, Maigret B, Bouisson M, et al. (1999) Evidence for a direct interaction between the penultimate aspartic acid of cholecystokinin and histidine 207, located in the second extracellular loop of the cholecystokinin B receptor. J Biol Chem 274:23191-23197.
33. Solano RM, Langer I, Perret J, Vertongen P, Juarranz MG, Robberecht P, and Waelbroeck M (2001) Two basic residues of the h-VPAC1 receptor second transmembrane helix are essential for ligand binding and signal transduction. J Biol Chem 276:1084-1088.
34. Turner PR, Mefford S, Bambino T, and Nissenson RA (1998) Transmembrane residues together with the amino terminus limit the response of the parathyroid hormone (PTH) 2 receptor to PTH-related peptide. J Biol Chem 273:3830-3837.
35. Vertongen P, Solano RM, Perret J, Langer I, Robberecht P, and Waelbroeck M (2001) Mutational analysis of the human vasoactive intestinal peptide receptor subtype VPAC(2): role of basic residues in the second transmembrane helix. Br J Pharmacol 133:1249-1254.
36. Volz A, Göke R, Lankat-Buttgereit B, Fehmann HC, Bode HP, and Göke B (1995) Molecular cloning, functional expression, and signal transduction of the GIP-receptor cloned from a human insulinoma. FEBS Lett 373:23-29.
37. Waelbroeck M, Perret J, Vertongen P, Van Craenenbroeck M, and Robberecht P (2002) Identification of secretin, vasoactive intestinal peptide and glucagon binding sites: from chimaeric receptors to point mutations. Biochem Soc Trans 30:437-441.